Andrew Cheng - May 18, 2021 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Stock symbol
VERA
Transactions as of
May 18, 2021
Transactions value $
$0
Form type
4
Date filed
5/18/2021, 08:12 PM
Previous filing
May 13, 2021
Next filing
Jun 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Conversion of derivative security +17.5K 17.5K May 18, 2021 See footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Series C Preferred Stock Conversion of derivative security $0 -17.5K -100% $0.00* 0 May 18, 2021 Class A Common Stock 17.5K See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.
F2 The shares are held of record by Andrew K. Cheng, as Trustee of the Andrew Cheng 2010 Trust UA 10-26-2010.